What's Happening?
MacroGenics, Inc. has entered into an agreement to sell its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million. The sale includes MacroGenics' biologics drug substance manufacturing facility in Rockville, Maryland, and a related warehouse
in Frederick, Maryland. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions. Bora will pay MacroGenics in cash at closing, with potential additional payments based on future manufacturing milestones. The agreement also includes a manufacturing and supply agreement, a transition services agreement, and a sublease agreement for part of the Rockville facility.
Why It's Important?
This transaction allows MacroGenics to streamline its operations and focus on its core competencies in drug development while providing Bora Pharmaceuticals with enhanced manufacturing capabilities in the U.S. The sale is expected to strengthen Bora's position in the biologics contract development and manufacturing organization (CDMO) market, enabling it to offer comprehensive services to biotech companies. For MacroGenics, the proceeds from the sale will support its strategic initiatives and potentially fund further research and development activities.
What's Next?
Following the completion of the sale, MacroGenics will continue to collaborate with Bora through the manufacturing and supply agreement, ensuring a smooth transition of operations. Bora plans to integrate the acquired facilities into its existing operations, leveraging the new capabilities to expand its service offerings. The transaction is anticipated to close in the third quarter of 2026, pending regulatory approvals and other closing conditions.
